• Search History (Register)
  • MeSH Browser

Welcome to the international HTA database


Showing [23806 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2022     Penn Medicine Center for Evidence-based Practice (CEP) Breast cancer risk assessment tools
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Voretigene neparvovec (inherited retinal dystrophy) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2022     Agency for Care Effectiveness (ACE) Magnetic resonance image guided radiation therapy for patients with cancer
2022     Penn Medicine Center for Evidence-based Practice (CEP) Testosterone reference ranges for gender diverse individuals
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Idebenone (Leber hereditary optic neuropathy) - assessment according to §35a (para. 1., sentence 11) Social Code Book V (expiry of the decision)]
2022     Agency for Care Effectiveness (ACE) Robot-assisted endovascular intervention systems for coronary artery disease and other vascular diseases
2022     Penn Medicine Center for Evidence-based Practice (CEP) Structured screening questionnaires for alcohol misuse/alcohol use disorders
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Somatrogon (growth disturbance) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Neuromuscular feedback therapy for paraplegia (Addendum to Commission E21-08)]
2022     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Home-based oral nutritional supplements in cancer patients who require modification of the usual ordinary diet due to mucositis]
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: updated recommendations for adjusting antidiabetic medication in type 2 diabetes]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Empagliflozin (heart failure) - Benefit assessment according to §35a Social Code Book V]
2022     Agency for Care Effectiveness (ACE) Nicotine replacement therapies to aid smoking cessation
2022     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Home-based oral nutritional supplements in cancer patients with moderate-severe malnutrition undergoing active treatment]
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: initiating pharmacological treatment for oropharyngeal mucositis in a patient receiving cancer therapy]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Review of age limits in the mammography screening programme]
2022     Agency for Care Effectiveness (ACE) Ciclosporin 0.1% eye drops for treating severe keratitis in dry eye disease
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: intravenous iron therapy in adults]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Transcervical radiofrequency ablation with intrauterine ultrasound guidance for uterine fibroids - Second addendum to commission H21-14]
2022     Agency for Care Effectiveness (ACE) Sodium zirconium cyclosilicate for treating hyperkalaemia
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: evaluation of the relevance of newborn screening for severe combined immunodeficiency SCID]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Casirivimab/imdevimab (post-exposure prophylaxis of COVID-19) - Benefit assessment according to §35a Social Code Book V]
2022     Agency for Care Effectiveness (ACE) Dolutegravir with lamivudine for treating Human Immunodeficiency Virus type 1 (HIV-1) infection
2022     Penn Medicine Center for Evidence-based Practice (CEP) Clinical utility of inpatient fall risk assessment
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Doravirine/lamivudine/tenofovir disoproxil (HIV infection) - Benefit assessment according to §Social Code Book V]
2022     Agency for Care Effectiveness (ACE) Acarbose for treating type 2 diabetes mellitus
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: assessment of insulin pump systems for type 1 diabetes patients]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Doravirine (HIV infection in adolescents) - Benefit assessment according to §35a Social Code Book V]
2022     Agency for Care Effectiveness (ACE) Ciclosporin 0.1% eye drops for treating severe vernal keratoconjunctivitis
2022     Norwegian Institute of Public Health (NIPH) Tests for the detection of NTRK gene fusions in patients with locally advanced or metastatic solid tumours
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: relevance of the prerequisite of the use of an immunosuppressant drug for the coverage of biologic agents (gastroenterology and dermatology)]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Brolucizumab (visual impairment due to diabetic macular oedema) - Benefit assessment according to §35a Social Code Book V]
2022     Agency for Care Effectiveness (ACE) Recombinant blood products for prophylaxis and management of haemophilia A and B
2022     Austrian Institute for Health Technology Assessment (AIHTA) CAR-T cell-therapies in development, update 2022
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Abemaciclib (breast cancer) - Benefit assessment according to §35a Social Code Book V]
2022     Agency for Care Effectiveness (ACE) GLP-1 receptor agonist injections for treating type 2 diabetes mellitus
2022     Austrian Institute for Health Technology Assessment (AIHTA) Regulation and financing of prenatal screening and diagnostic examinations for fetal anomalies in selected European countries
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Nivolumab (urothelial carcinoma, adjuvant) - Benefit assessment according to §35a Social Code Book V]
2022     NIHR Health Technology Assessment programme Modelling approaches for histology-independent cancer drugs to inform NICE appraisals: a systematic review and decision-framework
2022     Austrian Institute for Health Technology Assessment (AIHTA) [Telemonitoring in Austrian diabetes care: a systematic analysis of evaluation methodologies]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Nivolumab (oesophageal squamous cell carcinoma) - Benefit assessment according to §35a Social Code Book V]
2022     Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Quality improvement strategies in trauma care: review and proposal of 31 novel quality indicators
2022     NIHR Health Services and Delivery Research programme Components of interventions to reduce restrictive practices with children and young people in institutional settings: the Contrast systematic mapping review
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Nivolumab (oesophageal cancer) - Benefit assessment according to §35a Social Code Book V]
2022     Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Achieving safe surgery after COVID-19 vaccination
2022     NIHR Health Services and Delivery Research programme Assessment and management pathways of older adults with mild cognitive impairment: descriptive review and critical interpretive synthesis
2022     Health Information and Quality Authority (HIQA) Health technology assessment of metabolic surgery for the treatment of comorbid type 2 diabetes and obesity
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Tebentafusp (uveal melanoma) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2022     Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Impact of COVID-19, gender, race, specialty and seniority on mental health during surgical training: an international study
2022     Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval) [Respiratory rehabilitation following hospitalization related to a diagnosis of COVID-19 - an update]
2022     Institute for Clinical and Economic Review (ICER) Betibeglogene autotemcel for beta thalassemia: effectiveness and value
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ceftazidime/avibactam (bacterial infection) - Assessment according to §35a (para. 1c) Social Code Book V]
2022     Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Mesh versus non-mesh repair of groin hernias: a rapid review
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [Newsletter: overview of early access mechanisms and conditional refund terms]
2022     Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval) [Screening tools for frailty in users undergoing cardiac surgery requiring a sternotomy]
2022     Institute for Clinical and Economic Review (ICER) Special assessment of outpatient treatments for COVID-19
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Imipenem/cilastatin/relebactam (bacterial infections) - Assessment according to §35a (para. 1c) Social Code Book V]
2022     Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Update: guidelines on the preoperative diagnostic workup for COVID-19
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [Newsletter: experiences and lessons learned with conditional refund terms]
2022     Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval) [Procalcitonin assay for optimizing the use of antibiotics in the treatment of infections]
2022     Institute for Clinical and Economic Review (ICER) Tirzepatide for type 2 diabetes
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ceftolozane/tazobactam (bacterial infections) - Assessment according to §35a (para. 1c) Social Code Book V]
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [Newsletter: drug costs -tracking Quebec spending and trends]
2022     Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval) [Anesthesia information management systems]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Axicabtagene ciloleucel (diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma) - Assessment according to §35a (para. 1, sentence 11) Social Code Book V (expiry of the decision)]
2022     Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval) [Pulmonary rehabilitation in people with chronic obstructive pulmonary disease (a briefing note)]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Sotrovimab (COVID-19, without supplemental oxygen, increased risk of severe disease) - Benefit assessment according to §35a Social Code Book V]
2022     Malaysian Health Technology Assessment (MaHTAS) Tertiary care virtual online consultation between doctor and patient
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Guideline synopsis for obesity - children and adolescents]
2022     NIHR Health Technology Assessment programme Daily low-dose prednisolone to prevent relapse of steroid-sensitive nephrotic syndrome in children with an upper respiratory tract infection: PREDNOS2 RCT
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Guideline synopsis for obesity - adults]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Cabozantinib (thyroid carcinoma) - Benefit assessment according to §35a Social Code Book V]
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [Anorectal biofeedback therapy in primary constipation]
2022     Ontario Health Transcatheter valve-in-valve implantation for degenerated mitral or tricuspid bioprosthetic valves: a health technology assessment
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Empagliflozin (heart failure and preserved ejection fraction) - Addendum to Commission A22-39]
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [Neurophysiological facial nerve monitoring during parotid gland surgery]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Polatuzumab vedotin (diffuse large B-cell lymphoma) - Assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [PSMA PET/CT staging in patients with prostate cancer biochemical recurrence]
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: high-dose vitamin C injections for cancer patients in Quebec]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Tisagenlecleucel (follicular lymphoma) - Assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [Lutetium 177 PSMA in patients with prostate cancer]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Enfortumab vedotin (urothelial cancer) - Benefit assessment according to §35a Social Code Book V]
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [Elexacaftor/tezacaftor/ivacaftor in cystic fibrosis]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Setmelanotide (obesity and control of hunger in POMC, PCSK1 or LEPR deficiency obesity) - Assessment according to §35a (para. 1, sentence 11) Social Code Book VAuftraggeber: G-BA]
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [Gated-SPECT in ischemic non-obstructive coronary artery disease (microvascular angina - INOCA)]
2022     Ontario Health Molecular testing for thyroid nodules with atypical cells of indeterminate significance
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [Vagus nerve stimulation for drug-resistant epilepsy]
2022     Canadian Agency for Drugs and Technologies in Health (CADTH) Adalimumab for the treatment of adults with non-infectious uveitis
2022     Ontario Health Genetic testing for familial hypercholesterolemia
2022     NIHR Health Technology Assessment programme Outcome after selective early closure of ductus arteriosus in extremely preterm babies (Baby-OSCAR trial)
2022     NIHR Health Technology Assessment programme One-session treatment compared with multisession CBT in children aged 7–16 years with specific phobias: the ASPECT non-inferiority RCT
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [308nm excimer laser or 308nm excimer light in patients with vitiligo]
2022     Canadian Agency for Drugs and Technologies in Health (CADTH) Adalimumab for the treatment of pediatric populations with non-infectious uveitis
2022     Ontario Health Pre-surgical nasal decolonization of staphylococcus aureus
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [Sialendoscopy for obstructive salivary gland disease]
2022     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Treatments for extreme nausea and vomiting in pregnancy (hyperemesis gravidarum)]
2022     Austrian Institute for Health Technology Assessment (AIHTA) Wearable cardioverter-defibrillator (WCD) therapy for primary and secondary prevention of sudden cardiac arrest. Update 2022
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [Fecal microbiota transplantation for recurrent Clostridioides difficile infection]
2022     Austrian Institute for Health Technology Assessment (AIHTA) Long COVID care pathways and structures: an updated scoping review
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [Casirivimab and imdevimab to treat Covid-19 in patients negative for the Omicron genotype]